Stockscreener 앱 받기
1.07
5.94%
0.06
시간 외 거래:
1.07
Fate Therapeutics Inc 주식(FATE)의 최신 뉴스
Robert W. Baird Cuts Fate Therapeutics (NASDAQ:FATE) Price Target to $4.00 - Defense World
Barclays Cuts Fate Therapeutics (NASDAQ:FATE) Price Target to $2.00 - Defense World
Wedbush Predicts Increased Earnings for Fate Therapeutics - Defense World
What is Leerink Partnrs’ Estimate for FATE Q2 Earnings? - Defense World
Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus - MSN
Needham & Company LLC Reiterates “Hold” Rating for Fate Therapeutics (NASDAQ:FATE) - Defense World
Fate Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Fate Therapeutics (FATE) Faces Significant Price Target Reductio - GuruFocus
FATE Stock Update: Analyst Lowers Price Target, Maintains Neutra - GuruFocus
4 Analysts Assess Fate Therapeutics: What You Need To Know - Benzinga
Barclays Adjusts Fate Therapeutics (FATE) Price Target Amid Q1 R - GuruFocus
Baird Revises Fate Therapeutics (FATE) Price Target Post-Q1 Resu - GuruFocus
FATE Therapeutics Exceeds Revenue Estimates with Strong CAR T-Ce - GuruFocus
Fate Therapeutics: Q1 Earnings Snapshot - CT Insider
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates - NewsBreak: Local News & Alerts
Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates - The Manila Times
FATE THERAPEUTICS INC SEC 10-Q Report - TradingView
What Is Going On With Fate Therapeutics Inc (NASDAQ: FATE)? - Stocksregister
Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Purchased by Dimensional Fund Advisors LP - Defense World
Hsbc Holdings PLC Has $179,000 Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Sold by MetLife Investment Management LLC - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Purchased by Wells Fargo & Company MN - Defense World
Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector - Seeking Alpha
Fate Therapeutics Inc (NASDAQ: FATE) Drops -18.14 Percent In Recent Trading, What Questions Do You Have? - Stocksregister
Fate Therapeutics Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of “Hold” by Brokerages - Defense World
Fate Therapeutics Inc [FATE] Records 50-Day SMA of $1.0480 - knoxdaily.com
LPL Financial LLC Buys New Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Uncovering the Potential of Fate Therapeutics Inc (FATE) Stock - investchronicle.com
There is no way Fate Therapeutics Inc (FATE) can keep these numbers up - Sete News
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting - The Manila Times
Fate Therapeutics to Present Clinical and Preclinical Data at ASGCT 28th Annual Meeting - Nasdaq
Was anything negative for Fate Therapeutics Inc (FATE) stock last session? - uspostnews.com
Fate Therapeutics Announces Five Presentations on - GlobeNewswire
The Attractiveness of Investing In Fate Therapeutics Inc (FATE) is Growing - knoxdaily.com
Geode Capital Management LLC Sells 31,279 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Recent uptick might appease Fate Therapeutics, Inc. (NASDAQ:FATE) institutional owners after losing 66% over the past year - Yahoo
Russell Investments Group Ltd. Increases Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
FATE CLASS ACTION: Hagens Berman Encourages Fate Therapeutics, Inc. (FATE) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Lawsuit Pending - ACCESS Newswire
FATE Shares Experience Decline in Value - knoxdaily.com
Analyzing Ratios: Fate Therapeutics Inc (FATE)’s Financial Story Unveiled - DWinneX
Ratios Revealed: Decoding Allarity Therapeutics Inc (ALLR)’s Financial Health - DWinneX
JPMorgan Chase & Co. Reduces Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics Inc [FATE] Stock trading around $1.25 per share: What’s Next? - dbtnews.com
Nothing is Better Than Fate Therapeutics Inc (FATE) stock at the moment - Sete News
Is Fate Therapeutics Inc (NASDAQ:FATE) stock a better investment at this time? - uspostnews.com
Franklin Resources Inc. Has $273,000 Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Vanguard Group Inc. Cuts Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag - MSN
Fate Therapeutics gets RMAT status from FDA for Lupus treatment - MSN
1.54%
7.58%
자본화:
|
볼륨(24시간):